CAI News & Events

Caris Life Sciences announced the commercial launch of Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence, the test analyzes a broad spectrum of molecular and biological signals associated with cancer, offering a more comprehensive approach than technologies that rely on limited genomic snapshots. Caris Detect's intended goal is to replace other outdated screening methods as the new standard of care for early detection of cancer. Caris Detect is powered by Caris' expansive molecular profiling database, which includes more than one million cases and over 50B molecular markers. This unparalleled dataset enables highly sophisticated AI models to detect subtle signals associated with early-stage disease across multiple cancer types.

Caris Life Sciences announced the dual listing of its common stock on NYSE Texas effective on June 17, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the Nasdaq, with a dual listing on the NYSE Texas under the same "CAI" ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.